Intuit stock is the worst performer in the Nasdaq 100 Index this year: buy the dip?
Intuit stock price has crashed this year and is now hovering at its lowest level since September 2020. INTU has plunged 62% from
Business
Business
Rocket Lab stock has crashed into a local bear market: will RKLB rebound?
Rocket Lab (NASDAQ: RKLB) stock has slipped into a local bear market after falling by 25% from its highest point this year. It
Business
Here’s why the S&P 500 Index, SPYM, SPY, and VOO ETFs may drop 5.4% soon
The S&P 500 Index has pulled back in the past few days, moving from the year-to-date high of $7,618 to $7,400. This retreat
Business
Soaring Astera Labs stock faces a major valuation risk: what next?
Astera Labs stock price has gone parabolic in the past few months, mirroring the performance of the semiconductor industry. ALAB jumped to $346
Business
Chainlink forecast: LINK stays below $8 despite network growth
LINK is down by less than 1% and continues to trade below $8. The coin staged a modest recovery after falling to a
Business
Oil market braces for shortages as reserves dwindle, conflict drags on
Global oil markets are facing renewed uncertainty as the conflict in the Middle East shows little sign of resolution, with Iran and Israel
Business
Commodity wrap: Oil slumps over 3% as Iran-Israel pause attacks; gold falls
Oil prices plunged more than 3% on Tuesday as Iran and Israel announced a halt in attacks, thereby easing tensions in the Middle
Investing
US dollar slips from recent highs as market focus shifts to inflation data
The US Dollar retreated from a two-month high during early European trading on Tuesday, with the US Dollar Index (DXY) falling to around
Economy
Monero (XMR) price forecast: Can the Cake Wallet integration spur a rebound?
Monero (XMR) price is down 21.5% over the past 30 days and sits nearly 60% below its all-time high of $797.73, which it
Economy
AstraZeneca’s obesity drug shows promise as analysts see upside beyond consensus
AstraZeneca is emerging as a potential new contender in the booming obesity treatment market after its experimental weight-loss pill delivered encouraging mid-stage trial